Hubei Hongyuan Pharmaceutical Technology Second Quarter 2024 Earnings: EPS: CN¥0.012 (vs CN¥0.001 in 2Q 2023)

Simply Wall St · 09/01 00:41

Hubei Hongyuan Pharmaceutical Technology (SZSE:301246) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥472.1m (down 4.4% from 2Q 2023).
  • Net income: CN¥4.61m (up by CN¥4.33m from 2Q 2023).
  • Profit margin: 1.0% (up from 0.1% in 2Q 2023). The increase in margin was driven by lower expenses.
  • EPS: CN¥0.012 (up from CN¥0.001 in 2Q 2023).
earnings-and-revenue-history
SZSE:301246 Earnings and Revenue History September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hubei Hongyuan Pharmaceutical Technology shares are up 4.4% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Hubei Hongyuan Pharmaceutical Technology (of which 1 is concerning!) you should know about.